Home Search
citius - search results
If you're not happy with the results, please do another search
VirnetX (VHC) Scores $440 Million and Citius Pharma (CTXR) Sees Market Expand to Over...
Internet Stock Review
Blast from the past scores big!
We added VirnetX (VHC)...
Citius (CTXR) Achieves 50% Patient Enrollment in Phase 3 Mino-Lok® Pivotal Trial
PHASE III PROGRESS
October 7th, 2019, Citius Completes 40% - Triggers Data Being Analyzed (is it working?).December 19th, 2019...
Okay, so What’s Next for Citius Pharma (CTXR) $1.16?
Dawson James Broker/Dealer Updates. Price Target Remains at $7.00.
"OK, So what’s Next? Topline data from the superior efficacy...
Citius Pharma (CTXR) $1.20. Price Target Upped to $4.00 at HC Wainright.
STREET INSIDER
H.C. Wainwright analyst Vernon Bernardino raised the price target on Citius Pharmaceuticals...
New Report: Citius Pharma (CTXR) Now Our #1 Ranked Idea for 2020.
Citius Pharmaceuticals (CTXR) is hands down one of the most exciting long-term opportunities we have come across since we first launched the...
Citius Pharma (CTXR) Corporate Presentation (Jan 2020).
In the above graphic, the catheter can get infected by bacteria and most typically see evidence of the infection (see gross graphic...
Citius Pharma (CTXR), Fortress Biotech (FBIO) and True Nature (TNTY) Significantly Higher on News.
Fortress Bio (FBIO, $2.42) Up 43%, Citius Pharma (CTXR, $1.15) Up 109% and True Nature Holdings (TNTY, $0.043) Up 117%, Since Adding...
Armistice Capital Master Fund Ltd., and Citius Pharma (CTXR).
April 2019 Offering
On April 1, 2019, Citius entered into securities purchase agreements with institutional investors and accredited investors...
Adding Citius (CTXR) $0.55 to Watch List.
Best Presentation at Dawson James Conference.
We attended the Dawson James Conference on October 29th, which had over 20...
Citius Pharma’s (CTXR) Mino-Lok® Highly Efficacious in Rapidly Eradicating Candida auris.
CRANFORD, N.J., May 13, 2019 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug...
Latest article
Nine Page Summary Report on GeoVax (GOVX)
This is a great long-term story. We’re telling you.
(March 2024) When we finished writing our earlier...
GeoVax (GOVX) Provides First Half 2024 Business Update.
Award of BARDA Project NextGen contract represents a significant milestone event;
Total value...
Reverse Split Mania! Solgenix (SNGX) Jumps 448% After 1:16.
Can You Imagine Selling Solgenix at $2.00 yesterday.
And to be honest, news wasn't all that big - such...
